Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents

Katherine J. Kayser-Bricker, Matthew P. Glenn, Sang Hoon Lee, Said M. Sebti, Jin Q. Cheng, Andrew D. Hamilton

Research output: Contribution to journalArticlepeer-review


Akt has emerged as a critical target for the development of anti-cancer therapies. It has been found to be amplified, overexpressed, or constitutively activated in numerous human malignancies with oncogenesis derived from the simultaneous promotion of cell survival and suppression of apoptosis. A valuable alternative to the more common ATP-mimetic based chemotherapies is a substrate-mimetic approach, which has the potential advantage of inherent specificity of the substrate-binding pocket. In this paper we present the development of high affinity non-peptidic, substrate-mimetic inhibitors based on the minimum GSK3β substrate sequence. Optimization of initial peptidic leads resulted in the development of several classes of small molecule inhibitors, which have comparable potency to the initial peptidomimetics, while eliminating the remaining amino acid residues. We have identified the first non-peptidic substrate-mimetic lead inhibitors of Akt 29a-b, which have affinities of 17 and 12 μM, respectively. This strategy has potential to provide a useful set of molecular probes to assist in the validation of Akt as a potential target for anti-cancer drug design.

Original languageEnglish (US)
Pages (from-to)1764-1771
Number of pages8
JournalBioorganic and Medicinal Chemistry
Issue number4
StatePublished - Feb 15 2009


  • Akt
  • Cancer
  • Inhibitor
  • Protein kinase B
  • Substrate-mimetic

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents'. Together they form a unique fingerprint.

Cite this